A VACCINE candidate has been found to be more than 90% effective in preventing Covid-19 in participants without symptoms of previous SARS-CoV-2 infection in a phase three late-stage study.
The results show an mRNA-based vaccine could help prevent the virus in most people who received it.
Albert Bourla, CEO of US pharmaceutical company Pfizer, said that meant they’re one step closer to providing people around the world with a much-needed breakthrough to end the pandemic.
Pfizer and German partner BioNTech have announced positive efficacy results, but stressed they couldn’t apply for emergency use authorisation based on these results alone. “More data on safety is also needed, and we are continuing to accumulate that data as part of our ongoing clinical study,” said Bourla.
He said it’s estimated that an average of two months of safety data after the second and final dose of the vaccine candidate was required by the Food and Drug Administration guidance for potential emergency use authorisation.
